COMPANY

Parion Sciences

HQ: Raleigh, NC source · parion.com ↗ · Southeast

Parion is currently developing the TPAD device in combination with hypertonic saline for the mobilization of mucus and sputum from patients with respiratory disorders. Our company was originally founded on advancing our proprietary epithelial sodium channel (“ENaC”) blockers for pulmonary diseases. From company website Source · Oct 13, 2026

Keywords: tpad Cystic Fibrosis Sjogren's Syndrome Dry Eye Disease Xerostomia Primary Ciliary Dyskinesia Dry Mouth Associated With Sjogren's Syndrome pulmonary disease VX-371 552-02 P-1037 P-552

Profile checked Oct 10, 2026

9Trials (company is sponsor)14NIH grants

Timeline

Aug 14, 2025 Grant Government grant — SBIR: $1.97M (annual award, as published), announced Aug 14, 2025. Agency: NIH/NHLBI. Source: government award database. source ↗
2016-08 Trial start Phase 2: Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia source ↗
2016-07 Trial start Phase 2: Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease source ↗
2016-07 Trial start Phase 2: Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease source ↗
2016-02 Trial start Phase 2: A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation source ↗
2015-04 Trial start Phase 2: Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF) source ↗
2014-07 Trial start Phase 1: Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease source ↗
2010-11 Trial start Phase 1/Phase 2: An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness source ↗
2009-02 Trial start Phase 2: A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome source ↗
2006-01 Trial start Phase 1/Phase 2: Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients source ↗

Funding

Last 2 years.

Aug 14, 2025 Government grant — SBIR: $1.97M (annual award, as published), announced Aug 14, 2025. Agency: NIH/NHLBI. Source: government award database. source ↗

Clinical trials (lead sponsor) 9

Record	Title	Phase	Status	Start	Primary completion
NCT02871778	Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia	Phase 2	Completed	2016-08	Nov 20, 2018 (actual)
NCT02709109	A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation	Phase 2	Completed	2016-02	2017-09 (actual)
NCT02343445	Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)	Phase 2	Completed	2015-04	2016-02 (actual)
NCT01369589	An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness	Phase 1/Phase 2	Completed	2010-11	2011-04 (actual)
NCT02831387	Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease	Phase 2	Terminated	2016-07	2017-06 (actual)
NCT00852839	A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome	Phase 2	Completed	2009-02	2009-10 (actual)
NCT02824913	Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease	Phase 2	Terminated	2016-07	2017-03 (actual)
NCT02242032	Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease	Phase 1	Completed	2014-07	2015-03 (actual)
NCT00274313	Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients	Phase 1/Phase 2	Completed	2006-01	Not listed

NIH awards 14

Annual award amounts. Total $7.8M.

Apr 26, 2024 NIH award 1R44HL174235-01 FY2024: $295,700 awarded for that fiscal year; activity R44 (SBIR); PI DONN, KARL H; recipient as written: PARION SCIENCES, INC., DURHAM, NC. A Novel ENaC Blocker/Osmolyte Inhalation Solutio source ↗
Jan 27, 2020 NIH award 1R43AI145766-01A1 FY2020: $274,173 awarded for that fiscal year; activity R43 (SBIR); PI DONN, KARL H; recipient as written: PARION SCIENCES, INC., DURHAM, NC. Novel Dual Acting Antibiotics for Pulmonary Di source ↗
Sep 5, 2013 NIH award 1R43HL112436-01A1 FY2013: $319,012 awarded for that fiscal year; activity R43 (SBIR); PI THELIN, BILL; recipient as written: PARION SCIENCES, INC., DURHAM, NC. Novel Mucolytic Agents source ↗
Aug 19, 2013 NIH award 2R44HL110502-02 FY2013: $1,509,420 awarded for that fiscal year; activity R44 (SBIR); PI DONN, KARL H; recipient as written: PARION SCIENCES, INC., DURHAM, NC. Hypertonic Saline for Cystic Fibrosis source ↗
Aug 23, 2011 NIH award 1R43HL110502-01 FY2011: $244,797 awarded for that fiscal year; activity R43 (SBIR); PI YERXA, BENJAMIN; recipient as written: PARION SCIENCES, INC., DURHAM, NC. Hypertonic Saline for Cystic Fibrosis source ↗
Jul 18, 2011 NIH award 2R44EY020705-02 FY2011: $1,059,726 awarded for that fiscal year; activity R44 (SBIR); PI DONN, KARL H; recipient as written: PARION SCIENCES, INC., DURHAM, NC. The Development Epithelial Sodium Channel Bloc source ↗
Apr 20, 2010 NIH award 1R43EY020705-01 FY2010: $159,264 awarded for that fiscal year; activity R43 (SBIR); PI DONN, KARL H; recipient as written: PARION SCIENCES, INC., DURHAM, NC. The Development Epithelial Sodium Channel Blocke source ↗
Apr 1, 2010 NIH award 3RC1AI081297-01S2 FY2010: $340,009 awarded for that fiscal year; activity RC1 (OTHER_NIH); PI DONN, KARL H; recipient as written: PARION SCIENCES, INC., DURHAM, NC. Novel Therapies for Enhancing Clearance o source ↗
Sep 21, 2009 NIH award 3RC1AI081297-01S1 FY2009: $500,000 awarded for that fiscal year; activity RC1 (OTHER_NIH); PI DONN, KARL H; recipient as written: PARION SCIENCES, INC., DURHAM, NC. Novel Therapies for Enhancing Clearance o source ↗
Aug 19, 2009 NIH award 9R44DE020042-02A1 FY2009: $379,296 awarded for that fiscal year; activity R44 (SBIR); PI DONN, KARL; recipient as written: PARION SCIENCES, INC., DURHAM, NC. PHARMACOTHERAPRY FOR XEROSTOMIA IN SJOGREN'S SYN source ↗
Sep 15, 2008 NIH award 1RC1AI081297-01 FY2008: $850,311 awarded for that fiscal year; activity RC1 (OTHER_NIH); PI DONN, KARL H; recipient as written: PARION SCIENCES, INC., DURHAM, NC. Novel Therapies for Enhancing Clearance of source ↗
Sep 4, 2006 NIH award 4R44HL082340-02 FY2006: $983,544 awarded for that fiscal year; activity R44 (SBIR); PI ST GEORGE, JUDITH A; recipient as written: PARION SCIENCES, INC., DURHAM, NC. DEVELOPMENT OF EPITHELIAL SODIUM CHANNEL source ↗
Sep 22, 2005 NIH award 1R43AR052986-01 FY2005: $489,999 awarded for that fiscal year; activity R43 (SBIR); PI HOPKINS, SAMUEL EARL; recipient as written: PARION SCIENCES, INC., DURHAM, NC. PHARMACOTHERAPY FOR XEROSTOMIA IN SJOGRE source ↗
Sep 19, 2005 NIH award 1R44HL082340-01 FY2005: $364,501 awarded for that fiscal year; activity R44 (SBIR); PI ST GEORGE, JUDITH A; recipient as written: PARION SCIENCES, INC., DURHAM, NC. DEVELOPMENT OF EPITHELIAL SODIUM CHANNEL source ↗